A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia.
Iris de WeerdtRoeland LamerisJurjen M RubenRenate de BoerJan KloostermanLisa A KingMark-David LevinPaul W H I ParrenTanja D de GruijlArnon P KaterHans J van der VlietPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Collectively, our data demonstrate the immunotherapeutic potential of this novel CD1d-specific Vγ9Vδ2-T cell engager in CLL.